carnitine

carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine. It plays an indispensable role in the transport of long-chain fatty acids into the mitochondrial matrix for β-oxidation and energy production. First isolated from meat extracts in 1905, its essential metabolic function was elucidated in the mid-20th century, leading to its classification as a conditionally essential nutrient. The biologically active form is L-carnitine, while its enantiomer D-carnitine is biologically inactive and can inhibit the function of the L-form.

Structure and biosynthesis

Carnitine is a small, water-soluble molecule with a chemical structure featuring a trimethylammonium group, a hydroxyl group, and a carboxylic acid moiety. Its biosynthesis in humans is a multi-step process primarily occurring in the liver, kidneys, and brain. The pathway begins with the methylation of the epsilon-amino group of lysine, catalyzed by enzymes utilizing S-adenosyl methionine as a methyl donor. Key enzymes in this cascade include trimethyllysine dioxygenase (TMLD), hydroxytrimethyllysine aldolase, and butyrobetaine hydroxylase, with the final step requiring ascorbic acid (vitamin C) and iron as cofactors. Genetic deficiencies in any of these enzymes, such as mutations in the TMLHE gene, can lead to primary carnitine deficiency.

Biological functions

The primary and most critical function is facilitating the transport of long-chain fatty acids across the inner mitochondrial membrane, a process essential for fatty acid β-oxidation. This is mediated by a shuttle system involving carnitine palmitoyltransferase I (CPT1) on the outer mitochondrial membrane, the transporter carnitine-acylcarnitine translocase (CACT), and carnitine palmitoyltransferase II (CPT2) on the inner membrane. Beyond this central role, it modulates the mitochondrial acetyl-CoA/CoA ratio by exporting excess acetyl groups as acetylcarnitine, which is crucial for maintaining metabolic flexibility. It also functions in the peroxisomal oxidation of very-long-chain fatty acids and may have antioxidant properties by scavenging reactive oxygen species.

Dietary sources and supplementation

Dietary intake is predominantly from animal products, with rich sources including red meat (particularly from beef and lamb), poultry, fish (like cod and salmon), and dairy products such as milk and cheese. Plant-based foods generally contain negligible amounts. For individuals with deficiencies or specific metabolic needs, supplementation is available in various forms including L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine. These supplements are marketed for potential benefits in exercise performance, with some studies supported by the International Society of Sports Nutrition, and in conditions like male infertility and cognitive decline. Regulatory bodies like the European Food Safety Authority and the U.S. Food and Drug Administration have evaluated specific health claims.

Clinical significance

Carnitine deficiency states are a major area of clinical focus, categorized as primary (genetic) or secondary. Primary systemic carnitine deficiency (SCD) is an autosomal recessive disorder caused by mutations in the SLC22A5 gene, which encodes the organic cation transporter novel type 2 (OCTN2). Secondary deficiencies can arise from inborn errors of metabolism (like medium-chain acyl-CoA dehydrogenase deficiency), renal dialysis, or drug therapies such as valproic acid. It is used therapeutically to treat these deficiencies and is investigated for potential roles in managing angina pectoris, peripheral arterial disease, and Alzheimer's disease. However, meta-analyses, including those by the Cochrane Collaboration, have shown mixed evidence for many proposed benefits beyond treating deficiency.

Metabolism and pharmacokinetics

Endogenous synthesis and dietary intake maintain body pools, with the highest concentrations found in tissues with high fatty acid oxidation rates like skeletal and cardiac muscle. Absorption from dietary sources occurs in the small intestine via both passive diffusion and active transport by the OCTN2 transporter. It is not extensively metabolized and is primarily eliminated by the kidneys via renal tubular reabsorption, a process also mediated by OCTN2. Pharmacokinetic studies show that oral bioavailability is relatively low (approximately 5-15%), and supplementation leads to a dose-dependent increase in plasma concentrations. The pharmacokinetics can be altered in patients with renal impairment, such as those undergoing treatment at the Mayo Clinic, necessitating dosage adjustments.

Category:Quaternary ammonium compounds Category:Dietary supplements Category:Metabolism